Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Hartwig P. Huemer; Birgit Strobl; Norbert Nowotny

doi:10.1016/S0264-410X(99)00413-2

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

Hartwig P. Huemer^*, Birgit Strobl, Norbert Nowotny

^*المؤلف المقابل لهذا العمل

نتاج البحث: المساهمة في مجلة › Article › مراجعة النظراء

14 اقتباسات (Scopus)

ملخص

The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

اللغة الأصلية	English
الصفحات (من إلى)	1320-1326
عدد الصفحات	7
دورية	Vaccine
مستوى الصوت	18
رقم الإصدار	14
المعرِّفات الرقمية للأشياء	https://doi.org/10.1016/S0264-410X(99)00413-2
حالة النشر	Published - فبراير 4 2000
منشور خارجيًا	نعم

ASJC Scopus subject areas

???subjectarea.asjc.1300.1313???
???subjectarea.asjc.2400.2400???
???subjectarea.asjc.3400.3400???
???subjectarea.asjc.2700.2739???
???subjectarea.asjc.2700.2725???

أهداف الأمم المتحدة للتنمية المستدامة

يساهم هذا المخرج في تحقيق أهداف الأمم المتحدة للتنمية المستدامة التالية (SDGs)

الوصول إلى المستند

10.1016/S0264-410X(99)00413-2

الملفات والروابط الأخرى

قم بذكر هذا

@article{444499cf5d1643568778f340b1ba0185,

title = "Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme",

abstract = "The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.",

keywords = "DNA vaccine, EHV, MVA, Vaccinia virus",

author = "Huemer, {Hartwig P.} and Birgit Strobl and Norbert Nowotny",

note = "Funding Information: The authors appreciated the help of Professor H. Walln{\"o}fer with the animal experiments. PD Dr. C.P. Cerny, LMU Munich, Germany and Dr. H. Shida, University of Kyoto, Japan are gratefully acknowledged for reagent donation as well as R. Stangl from Canberra Packard for the supply of the luminescence equipment and reagents. The work has been supported by the Austrian Academy of Sciences program for the advancement of research and technology (APART) and the Jubil{\"a}umsfonds of the Austrian National Bank.",

year = "2000",

month = feb,

day = "4",

doi = "10.1016/S0264-410X(99)00413-2",

language = "English",

volume = "18",

pages = "1320--1326",

journal = "Vaccine",

issn = "0264-410X",

publisher = "Elsevier BV",

number = "14",

}

TY - JOUR

T1 - Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

AU - Huemer, Hartwig P.

AU - Strobl, Birgit

AU - Nowotny, Norbert

N1 - Funding Information: The authors appreciated the help of Professor H. Wallnöfer with the animal experiments. PD Dr. C.P. Cerny, LMU Munich, Germany and Dr. H. Shida, University of Kyoto, Japan are gratefully acknowledged for reagent donation as well as R. Stangl from Canberra Packard for the supply of the luminescence equipment and reagents. The work has been supported by the Austrian Academy of Sciences program for the advancement of research and technology (APART) and the Jubiläumsfonds of the Austrian National Bank.

PY - 2000/2/4

Y1 - 2000/2/4

N2 - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

AB - The nonreplicating chicken adapted vaccinia virus strain MVA was used in a combined vaccine scheme. Using the equine herpesvirus type 1 (EHV-1) encoded complement-receptor glycoprotein C as antigen, only poor antibody response was induced by exclusive vaccination with DNA plasmids. The administration of recombinant MVA followed by plasmid immunization elicited both humoral and cellular immune responses in hamster comparable to EHV-1 full virus vaccines. Our results indicate that recombinant constructs based on MVA represent a safe and efficient way to overcome problems of poor immunogenicity of certain antigens upon intramuscular DNA vaccination, thus replacing sophisticated adjuvants or application methods, which are not readily applicable in routine practice.

KW - DNA vaccine

KW - EHV

KW - MVA

KW - Vaccinia virus

UR - http://www.scopus.com/inward/record.url?scp=0033957536&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033957536&partnerID=8YFLogxK

U2 - 10.1016/S0264-410X(99)00413-2

DO - 10.1016/S0264-410X(99)00413-2

M3 - Article

C2 - 10618528

AN - SCOPUS:0033957536

SN - 0264-410X

VL - 18

SP - 1320

EP - 1326

JO - Vaccine

JF - Vaccine

IS - 14

ER -

Use of apathogenic vaccinia virus MVA expressing EHV-1 gC as basis of a combined recombinant MVA/DNA vaccination scheme

ملخص

ASJC Scopus subject areas

أهداف الأمم المتحدة للتنمية المستدامة

الوصول إلى المستند

الملفات والروابط الأخرى

بصمة

قم بذكر هذا